218 related articles for article (PubMed ID: 25029121)
1. Best practices recommendations in the application of immunohistochemistry in the bladder lesions: report from the International Society of Urologic Pathology consensus conference.
Amin MB; Trpkov K; Lopez-Beltran A; Grignon D;
Am J Surg Pathol; 2014 Aug; 38(8):e20-34. PubMed ID: 25029121
[TBL] [Abstract][Full Text] [Related]
2. Best practices recommendations in the application of immunohistochemistry in the prostate: report from the International Society of Urologic Pathology consensus conference.
Epstein JI; Egevad L; Humphrey PA; Montironi R;
Am J Surg Pathol; 2014 Aug; 38(8):e6-e19. PubMed ID: 25029122
[TBL] [Abstract][Full Text] [Related]
3. Utility of a comprehensive immunohistochemical panel in the differential diagnosis of spindle cell lesions of the urinary bladder.
Westfall DE; Folpe AL; Paner GP; Oliva E; Goldstein L; Alsabeh R; Gown AM; Amin MB
Am J Surg Pathol; 2009 Jan; 33(1):99-105. PubMed ID: 18941404
[TBL] [Abstract][Full Text] [Related]
4. Detection of residual tumor cells in bladder biopsy specimens: pitfalls in the interpretation of cytokeratin stains.
Tamas EF; Epstein JI
Am J Surg Pathol; 2007 Mar; 31(3):390-7. PubMed ID: 17325480
[TBL] [Abstract][Full Text] [Related]
5. The role of immunohistochemistry in the diagnosis of flat urothelial lesions: a study using CK20, CK5/6, P53, Cd138, and Her2/Neu.
Jung S; Wu C; Eslami Z; Tanguay S; Aprikian A; Kassouf W; Brimo F
Ann Diagn Pathol; 2014 Feb; 18(1):27-32. PubMed ID: 24321464
[TBL] [Abstract][Full Text] [Related]
6. Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia.
Aron M; Luthringer DJ; McKenney JK; Hansel DE; Westfall DE; Parakh R; Mohanty SK; Balzer B; Amin MB
Am J Surg Pathol; 2013 Dec; 37(12):1815-23. PubMed ID: 24225842
[TBL] [Abstract][Full Text] [Related]
7. Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the International Society of Urological Pathology consensus conference.
Amin MB; Epstein JI; Ulbright TM; Humphrey PA; Egevad L; Montironi R; Grignon D; Trpkov K; Lopez-Beltran A; Zhou M; Argani P; Delahunt B; Berney DM; Srigley JR; Tickoo SK; Reuter VE;
Am J Surg Pathol; 2014 Aug; 38(8):1017-22. PubMed ID: 25025364
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the WHO/ISUP classification and cytokeratin 20 expression in predicting the behavior of low-grade papillary urothelial tumors. World/Health Organization/Internattional Society of Urologic Pathology.
Alsheikh A; Mohamedali Z; Jones E; Masterson J; Gilks CB
Mod Pathol; 2001 Apr; 14(4):267-72. PubMed ID: 11301341
[TBL] [Abstract][Full Text] [Related]
9. Utility of p63 and high molecular weight cytokeratin in the distinction between urothelial carcinoma with prostatic stromal invasion and urothelial carcinoma with colonisation of prostatic ducts and acini.
Chastain EC; Oliva IV; Osunkoya AO
Pathology; 2012 Apr; 44(3):199-203. PubMed ID: 22406481
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: a study of 45 cases.
Oliva E; Pinheiro NF; Heney NM; Kaufman DS; Shipley WU; Gurski C; Spicer B; Paner GP; Gown AM; Amin MB
Hum Pathol; 2013 May; 44(5):860-6. PubMed ID: 23199526
[TBL] [Abstract][Full Text] [Related]
11. Best practices recommendations in the application of immunohistochemistry in testicular tumors: report from the International Society of Urological Pathology consensus conference.
Ulbright TM; Tickoo SK; Berney DM; Srigley JR;
Am J Surg Pathol; 2014 Aug; 38(8):e50-9. PubMed ID: 24832161
[TBL] [Abstract][Full Text] [Related]
12. Best practices recommendations in the application of immunohistochemistry in the kidney tumors: report from the International Society of Urologic Pathology consensus conference.
Reuter VE; Argani P; Zhou M; Delahunt B;
Am J Surg Pathol; 2014 Aug; 38(8):e35-49. PubMed ID: 25025368
[TBL] [Abstract][Full Text] [Related]
13. Dysplasia and carcinoma in situ of the urinary bladder.
Lopez-Beltran A; Marques RC; Montironi R; Reymundo C; Fonseca J; Cheng L
Anal Quant Cytopathol Histpathol; 2015 Feb; 37(1):29-38. PubMed ID: 26072632
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical evaluation of novel and traditional markers associated with urothelial differentiation in a spectrum of variants of urothelial carcinoma of the urinary bladder.
Paner GP; Annaiah C; Gulmann C; Rao P; Ro JY; Hansel DE; Shen SS; Lopez-Beltran A; Aron M; Luthringer DJ; De Peralta-Venturina M; Cho Y; Amin MB
Hum Pathol; 2014 Jul; 45(7):1473-82. PubMed ID: 24780825
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of antibody to smoothelin in the distinction of muscularis propria from muscularis mucosae of the urinary bladder: a potential ancillary tool in the pathologic staging of invasive urothelial carcinoma.
Paner GP; Shen SS; Lapetino S; Venkataraman G; Barkan GA; Quek ML; Ro JY; Amin MB
Am J Surg Pathol; 2009 Jan; 33(1):91-8. PubMed ID: 18936687
[TBL] [Abstract][Full Text] [Related]
16. Potential utility of uroplakin III, thrombomodulin, high molecular weight cytokeratin, and cytokeratin 20 in noninvasive, invasive, and metastatic urothelial (transitional cell) carcinomas.
Parker DC; Folpe AL; Bell J; Oliva E; Young RH; Cohen C; Amin MB
Am J Surg Pathol; 2003 Jan; 27(1):1-10. PubMed ID: 12502922
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of contemporary prostate and urothelial lineage biomarkers in a consecutive cohort of poorly differentiated bladder neck carcinomas.
Mohanty SK; Smith SC; Chang E; Luthringer DJ; Gown AM; Aron M; Amin MB
Am J Clin Pathol; 2014 Aug; 142(2):173-83. PubMed ID: 25015857
[TBL] [Abstract][Full Text] [Related]
18. Invasive urothelial carcinoma with chordoid features: a report of 12 distinct cases characterized by prominent myxoid stroma and cordlike epithelial architecture.
Cox RM; Schneider AG; Sangoi AR; Clingan WJ; Gokden N; McKenney JK
Am J Surg Pathol; 2009 Aug; 33(8):1213-9. PubMed ID: 19542871
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical differentiation of high-grade prostate carcinoma from urothelial carcinoma.
Chuang AY; DeMarzo AM; Veltri RW; Sharma RB; Bieberich CJ; Epstein JI
Am J Surg Pathol; 2007 Aug; 31(8):1246-55. PubMed ID: 17667550
[TBL] [Abstract][Full Text] [Related]
20. Placental S100 (S100P) and GATA3: markers for transitional epithelium and urothelial carcinoma discovered by complementary DNA microarray.
Higgins JP; Kaygusuz G; Wang L; Montgomery K; Mason V; Zhu SX; Marinelli RJ; Presti JC; van de Rijn M; Brooks JD
Am J Surg Pathol; 2007 May; 31(5):673-80. PubMed ID: 17460449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
